Apogee Therapeutics, Inc. APGE Stock Forecast
AI-powered price prediction and analysis for Apogee Therapeutics, Inc. ยท Last analysis Sep 14, 2026
Last analysis on September 14, 2026; a refreshed forecast appears once the daily run covers this ticker again.
This forecast was produced 6 trading days ago and has not been refreshed since; read it as historical, not as a current view.
Price Chart
Key Statistics
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. (APGE) operates in the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. .
Latest News
Where APGE sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | Ticker | AI Signal | Market Cap | P/E |
|---|---|---|---|---|
| Amgen Inc | AMGN | โโ% | $212.55B | 24.3x |
| Gilead Sciences, Inc. | GILD | โโ% | $186.69B | -x |
| Moderna, Inc. | MRNA | โโ% | $61.50B | -x |
| Argenx Se | ARGX | โโ% | $61.15B | -x |
| Revolution Medicines, Inc. | RVMD | โโ% | $40.93B | -x |
| Biogen Inc. | BIIB | โโ% | $32.34B | 23.6x |
| Biontech Se | BNTX | โโ% | $24.78B | -x |
| Mesoblast Ltd | MESO | โโ% | $19.62B | -x |
| Neurocrine Biosciences Inc | NBIX | โโ% | $14.86B | 21.1x |
| Exelixis, Inc. | EXEL | โโ% | $14.18B | -x |
| Halozyme Therapeutics, Inc. | HALO | โโ% | $12.65B | 30.6x |
| Bio-Techne Corp | TECH | โโ% | $11.35B | 62.4x |
| Twist Bioscience Corp | TWST | โโ% | $10.47B | -x |
| Repligen Corp | RGEN | โโ% | $9.98B | 240.3x |
| Krystal Biotech, Inc. | KRYS | โโ% | $9.97B | 41.3x |
| Kymera Therapeutics, Inc. | KYMR | โโ% | $9.79B | -x |
| Qiagen N.V. | QGEN | โโ% | $9.40B | -x |
| Immunitybio, Inc. | IBRX | โโ% | $8.99B | -x |
| Vaxcyte, Inc. | PCVX | โโ% | $8.65B | -x |
| Immunovant, Inc. | IMVT | โโ% | $7.63B | -x |
| Cg Oncology, Inc. | CGON | โโ% | $6.94B | -x |
| Scholar Rock Holding โฆ | SRRK | โโ% | $5.68B | -x |
| Crispr Therapeutics Ag | CRSP | โโ% | $5.64B | -x |
| Iovance Biotherapeutics, Inc. | IOVA | โโ% | $4.64B | -x |
| Adaptive Biotechnologies Corp | ADPT | โโ% | $4.45B | -x |
| Relay Therapeutics, Inc. | RLAY | โโ% | $4.13B | -x |
| Dbv Technologies S.A. | DBVT | โโ% | $3.58B | -x |
| Tarsus Pharmaceuticals, Inc. | TARS | โโ% | $3.43B | -x |
| Denali Therapeutics Inc. | DNLI | โโ% | $3.27B | -x |
| Beam Therapeutics Inc. | BEAM | โโ% | $2.61B | -x |
| Biocryst Pharmaceuticals Inc | BCRX | โโ% | $2.24B | -x |
| Scinai Immunotherapeutics Ltd. | SCNI | โโ% | $2.16B | -x |
| Adma Biologics, Inc. | ADMA | โโ% | $2.13B | 12.6x |
| Kodiak Sciences Inc. | KOD | โโ% | $2.06B | -x |
| Recursion Pharmaceuticals, Inc. | RXRX | โโ% | $2.05B | -x |
| Vericel Corp | VCEL | โโ% | $2.05B | 84.6x |
| Alvotech | ALVO | โโ% | $1.83B | -x |
| Vir Biotechnology, Inc. | VIR | โโ% | $1.79B | -x |
| Hemab Therapeutics Holdings, โฆ | COAG | โโ% | $1.77B | -x |
| Novavax Inc | NVAX | โโ% | $1.67B | -x |
| Immunocore Holdings Plc | IMCR | โโ% | $1.65B | -x |
| Taysha Gene Therapies, โฆ | TSHA | โโ% | $1.64B | -x |
| Cullinan Therapeutics, Inc. | CGEM | โโ% | $1.37B | -x |
| Meiragtx Holdings Plc | MGTX | โโ% | $1.27B | 16.1x |
| Vor Biopharma Inc. | VOR | โโ% | $1.27B | -x |
| Maze Therapeutics, Inc. | MAZE | โโ% | $1.25B | -x |
| Replimune Group, Inc. | REPL | โโ% | $1.23B | -x |
| Zura Bio Ltd | JATT | โโ% | $1.17B | -x |
| Odyssey Therapeutics, Inc. | ODTX | โโ% | $1.17B | -x |
| Immatics N.V. | IMTX | โโ% | $1.17B | -x |
| Valneva Se | VALN | โโ% | $1.14B | -x |
| Monte Rosa Therapeutics, โฆ | GLUE | โโ% | $1.05B | -x |
| Solid Biosciences Inc. | SLDB | โโ% | $955M | -x |
| Sana Biotechnology, Inc. | SANA | โโ% | $928M | -x |
| Candel Therapeutics, Inc. | CADL | โโ% | $858M | -x |
| 4d Molecular Therapeutics, โฆ | FDMT | โโ% | $841M | -x |
| Aura Biosciences, Inc. | AURA | โโ% | $660M | -x |
| Allogene Therapeutics, Inc. | ALLO | โโ% | $584M | -x |
| Prime Medicine, Inc. | PRME | โโ% | $566M | -x |
| Ginkgo Bioworks Holdings, โฆ | DNA | โโ% | $537M | -x |
FAQ
-
Is Apogee Therapeutics, Inc. a good stock to buy?
Our AI analyzes Apogee Therapeutics, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
-
How accurate are Apogee Therapeutics, Inc. predictions?
A per-ticker accuracy statistic for APGE is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
-
How often are forecasts updated?
Apogee Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on September 14, 2026.
Ready to invest smarter?
Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Apogee Therapeutics, Inc.?
View full institutional-grade analysis on Intratio โAI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.